Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)
May 10, 2021 06:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma
May 04, 2021 07:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
April 28, 2021 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial
April 19, 2021 06:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
April 11, 2021 16:01 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress
March 29, 2021 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals to Present Data at the 2021 American Association for Cancer Research (AACR) Annual Meeting
March 10, 2021 16:30 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team
January 04, 2021 16:30 ET | Checkmate Pharmaceuticals Inc.
Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI)...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab
December 08, 2020 07:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate Pharmaceuticals”), a clinical stage biopharmaceutical company focused on developing its...
Checkmate_FullColor.jpg
Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress
November 13, 2020 07:00 ET | Checkmate Pharmaceuticals Inc.
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary...